Pharmacokinetics of medetomidine in ponies and elaboration of a medetomidine infusion regime which provides a constant level of sedation.

This study investigates the behavior of the drug medetomidine in the bodies of ponies and proposes a method of administering this medication to maintain a consistent level of sedation.

Research Overview

• Researchers conducted a study to understand the pharmacokinetic properties of medetomidine in ponies. Pharmacokinetics is the study of how a drug is absorbed, distributed, metabolized, and excreted by the body. Medetomidine is a sedative often used in veterinary medicine.
• For this experiment, the drug was intravenously administered to five ponies. The amount used was 7 mcg per kg of the pony’s weight. The researchers observed how the drug behaved in the bodies of the ponies, and modelled the findings using a two-compartment model, a mathematical model that describes the body as two compartments (usually the blood and the rest of the body) to explain how the drug is distributed and eliminated.

Results

• The results showed that the clearance from the bodies of the ponies was 4 l/kg/h. The half-life of the drug was found to be around 7.6 minutes (t1/2alpha represents the half-life period connected to the drug distribution phase) and around 51.3 minutes (t1/2beta denotes the half-life period related the elimination phase of the drug), indicating that the drug is quickly absorbed and removed by the body.
• Out of the five, one pony demonstrated characteristics best suited for a one-compartment model, showing body clearance of 4.2 l/kg/h and a half-life of 11 minutes.
• In all cases, the study found that within 4 hours medetomidine plasma concentrations had dropped below the limit of quantification, meaning the concentration was so low it could not be accurately measured.
• To achieve a consistent level of sedation, the researchers proposed an infusion plan. In this plan, an initial dosage of 5 mcg/kg was given, followed by a stable infusion of 3.5 mcg/kg/h for two hours. This led to steady state plasma levels of medetomidine (1-1.5 ng/ml) within 30 minutes. The steady state is the point at which the amount of drug being administered and the amount being eliminated are equal, ensuring a constant concentration of the drug in the body.
• This sedation could be effectively reversed using another drug, atipamezole, at a dosage of 60 mcg/kg.

Conclusion

• The rapid absorption, distribution and clearance of medetomidine, coupled with its ability to produce a consistent level of sedation when administered as an infusion, make it suitable for long term use. This makes it an ideal choice for a total intravenous anesthetic technique in horses, where extended periods of sedation may be required.